According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

As we expand the benefits of Dupixent to more patients, we're pleased with the continued work on new indications including EoE for children in the EU, CSU outside Japan and BP globally.

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Dupixent, Adbry, and Ebglyss are FDA-approved only for the atopic dermatitis form of eczema. It is possible, however, that healthcare providers might also prescribe these medicines off-label for other ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

“Broken skin barriers” are real. They’re the subject of great interest from " skinfluencers " on TikTok, but they’re also ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.71. Thomas Larsen: Welcome to the Q4 and Full Year 2024 Conference Call ...

The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...